• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Kyverna Therapeutics Inc.

    3/27/25 4:53:22 PM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $KYTX alert in real time by email
    S-8 1 s-8_evergreen_mar_2025.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on March 27, 2025

    Registration No. 333-

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    Kyverna Therapeutics, Inc.

    (Exact name of registrant as specified in its charter)

    Delaware

    83-1365411

    (State or other jurisdiction of incorporation or organization)

    (I.R.S. Employer Identification No.)

    5980 Horton St., STE 550

    Emeryville, CA 94608

    (Address of Principal Executive Offices) (Zip Code)

    Kyverna Therapeutics, Inc. 2024 Equity Incentive Plan

    Kyverna Therapeutics, Inc. 2024 Employee Stock Purchase Plan

    (Full title of the plans)

    Warner Biddle

    Chief Executive Officer

    Kyverna Therapeutics, Inc.

    5980 Horton St., STE 550

    Emeryville, CA 94608

    (510) 925-2492

    (Name, address and telephone number, including area code, of agent for service)

     

    Copies to:

     

    Jeffrey T. Hartlin

    Samantha H. Eldredge

    Paul Hastings LLP

    1117 S. California Avenue

    Palo Alto, California 94304
    (650) 320-1800

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

    Emerging growth company

    ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     


     

    REGISTRATION OF ADDITIONAL SECURITIES

    Kyverna Therapeutics, Inc. (the “Registrant”) has prepared this Registration Statement on Form S-8 (the “Registration Statement”) in accordance with the requirements of Form S-8 under the Securities Act of 1933, as amended (the “Securities Act”), to register (i) 2,160,745 additional shares of common stock, $0.00001 par value per share (“Common Stock”), of the Registrant issuable pursuant to the Kyverna Therapeutics, Inc. 2024 Equity Incentive Plan (the “2024 Plan”) and (ii) 422,000 additional shares of Common Stock issuable pursuant to the Kyverna Therapeutics, Inc. 2024 Employee Stock Purchase Plan (the “2024 ESPP”). The Registrant’s stockholders have previously approved the 2024 Plan and the 2024 ESPP, including the shares of Common Stock available for issuance pursuant thereto.

    Pursuant to the Registration Statement on Form S-8 (File No. 333-276952) filed by the Registrant with the Securities and Exchange Commission (the “Commission”) on February 8, 2024 (the “Prior Registration Statement”), the Registrant previously registered an aggregate of 4,215,000 shares of Common Stock under the 2024 Plan and 422,000 shares of Common Stock under the 2024 ESPP.

    In accordance with General Instruction E to Form S-8, the contents of the Prior Registration Statement are hereby incorporated by reference.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE.

    The following documents filed by the Registrant with the Commission are hereby incorporated by reference into this Registration Statement:

     

    (a)

    The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on March 27, 2025;

     

     

     

    (b)

    The Registrant’s Current Report on Form 8-K filed with the Commission on January 21, 2025; and

     

     

     

    (c)

    The description of the Registrant’s common stock set forth in the Registration Statement on Form 8-A filed with the Commission on February 5, 2024 (File No. 001-41947) pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendments or reports filed for the purpose of updating such description, including the description of the Registrant’s securities included as Exhibit 4.2 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Commission on March 26, 2024.

    All other reports and other documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part of this Registration Statement from the date of the filing of such reports and documents, except as to any portion of any future annual or quarterly report to stockholders or document or current report furnished under Items 2.02 or 7.01 of Form 8-K that is not deemed filed under such provisions.

    For the purposes of this Registration Statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    You should rely only on the information provided or incorporated by reference in this Registration Statement or any related prospectus. The Registrant has not authorized anyone to provide you with different information. You

     

     

     


     

    should not assume that the information in this Registration Statement or any related prospectus is accurate as of any date other than the date on the front of the document.

    You may contact the Registrant in writing or orally to request copies of the above-referenced filings, without charge (excluding exhibits to such documents unless such exhibits are specifically incorporated by reference into the information incorporated into this Registration Statement). Requests for such information should be directed to:

     

    Kyverna Therapeutics, Inc.

    5980 Horton St., STE 550

    Emeryville, CA 94608

    (510) 925-2492

    Attn: Chief Executive Officer

    ITEM 4. DESCRIPTION OF SECURITIES.

    Not applicable.

    ITEM 5. INTERESTS OF NAMED EXPERTS AND COUNSEL.

    Not applicable.

    ITEM 6. INDEMNIFICATION OF DIRECTORS AND OFFICERS.

    Section 145 of the General Corporation Law of the State of Delaware, or the DGCL, authorizes a corporation’s board of directors to grant, and authorizes a court to award, indemnity to officers, directors and other corporate agents.

    The Registrant’s amended and restated certificate of incorporation and amended and restated bylaws contain provisions that limit the liability of the Registrant’s directors and officers for monetary damages to the fullest extent permitted by Delaware law. Consequently, the Registrant’s directors and officers will not be personally liable to the Registrant or the Registrant’s stockholders for monetary damages for any breach of fiduciary duties as directors or officers, except liability for the following:

    •
    any breach of their duty of loyalty to the Registrant or the Registrant’s stockholders;
    •
    any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
    •
    with respect to directors, unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the DGCL;
    •
    with respect to officers, derivative claims brought on behalf of the Registrant; or
    •
    any transaction from which they derived an improper personal benefit.

    Any amendment to, or repeal of, these provisions will not eliminate or reduce the effect of these provisions in respect of any act, omission or claim that occurred or arose prior to that amendment or repeal. If the DGCL is amended to provide for further limitations on the personal liability of directors or officers of corporations, then the personal liability of the Registrant’s directors and officers will be further limited to the greatest extent permitted by the DGCL.

    The Registrant’s amended and restated certificate of incorporation also provides that the Registrant will indemnify, to the fullest extent permitted by law, each person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative by reason of the fact that he or she is or was, or has agreed to become, a director or officer of the Registrant, or is or was serving, or has agreed to serve, at the request of the Registrant, as a director, officer, incorporator, employee or agent of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise, or by reason of any action alleged to have been taken or omitted in such capacity. In addition, the Registrant’s amended and restated certificate of incorporation provides that the Registrant must advance expenses incurred by or on behalf of a director or officer in advance of the final disposition of any action or proceeding, subject to very limited exceptions.

     

     

     


     

    Further, the Registrant has entered into, and expects to continue to enter into, indemnification agreements with each of its directors and executive officers that may be broader than the specific indemnification provisions contained in the DGCL. These indemnification agreements require the Registrant, among other things, to indemnify its directors and executive officers against liabilities that may arise by reason of their status or service. These indemnification agreements also require the Registrant to advance all expenses incurred by the directors and executive officers in investigating or defending any such action, suit or proceeding, subject to certain exceptions. The Registrant believes that these agreements are necessary to attract and retain qualified individuals to serve as directors and executive officers.

    The limitation of liability and indemnification provisions that are included in the Registrant’s amended and restated certificate of incorporation, amended and restated bylaws and in indemnification agreements that the Registrant enters into with its directors and executive officers may discourage stockholders from bringing a lawsuit against its directors and executive officers for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against the Registrant’s directors and executive officers even though an action, if successful, might benefit the Registrant and other stockholders. Further, a stockholder’s investment may be adversely affected to the extent that the Registrant pays the costs of settlement and damage awards against directors and executive officers as required by these indemnification provisions. Except as may be disclosed in this Registration Statement or the reports or documents incorporated by reference herein, the Registrant is not aware of any pending litigation or proceeding involving any person who is or was one of its directors, officers, employees or other agents or is or was serving at its request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, for which indemnification is sought, and the Registrant is not aware of any threatened litigation that may result in claims for indemnification.

    The Registrant’s amended and restated bylaws provide that the Registrant may purchase and maintain insurance, at its expense, to protect itself and any person who is or was a director, officer, employee or agent of the Registrant or is or was serving at its request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any expense, liability or loss, whether or not the Registrant would have the power to indemnity such person against such expense, liability or loss under the DGCL. The Registrant has obtained insurance under which, subject to the limitations of the insurance policies, coverage is provided to the Registrant’s directors and executive officers against loss arising from claims made by reason of breach of fiduciary duty or other wrongful acts as a director or executive officer, including claims relating to public securities matters, and to the Registrant with respect to payments that may be made by the Registrant to these directors and executive officers pursuant to the Registrant’s indemnification obligations or otherwise as a matter of law.

    ITEM 7. EXEMPTION FROM REGISTRATION CLAIMED.

    Not applicable.

    ITEM 8. EXHIBITS.

    Exhibit Number

    Description

    3.1

    Amended and Restated Certificate of Incorporation of Kyverna Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on February 12, 2024).

    3.2

    Amended and Restated Bylaws of Kyverna Therapeutics, Inc. (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed with the SEC on February 12, 2024).

    4.1

    Form of Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1 (File No. 333-276523), filed on January 16, 2024).

    5.1*

    Opinion of Paul Hastings LLP.

     

     

     


     

    10.1

    Kyverna Therapeutics, Inc. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Registrant’s Registration Statement on Form S-8 (File No. 333-276952), filed on February 8, 2024).

     

     

     

    10.2

    Kyverna Therapeutics, Inc. 2024 Equity Incentive Plan Form of Stock Option Agreement (incorporated by reference to Exhibit 10.3 to the Registrant’s Registration Statement on Form S-1/A (File No. 333-276523), filed on February 1, 2024).

     10.3

     

    Kyverna Therapeutics, Inc. 2024 Equity Incentive Plan Form of Restricted Stock Unit Award Agreement (incorporated by reference to Exhibit 10.4 to the Registrant’s Registration Statement on Form S-1/A (File No. 333-276523), filed on February 6, 2024.

     

     

     

    10.4

    Kyverna Therapeutics, Inc. 2024 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.5 to the Registrant’s Registration Statement on Form S-8 (File No. 333-276952), filed on February 8, 2024).

     

     

     

    23.1*

    Consent of BDO USA, P.C., Independent Registered Public Accounting Firm.

    23.2*

    Consent of Paul Hastings LLP (included in Exhibit 5.1).

    24.1*

    Power of Attorney is contained on the signature page.

    107*

    Filing Fee Table.

    * Filed herewith.

    ITEM 9. UNDERTAKINGS.

    (a) The Registrant hereby undertakes:

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

    (ii) To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement;

    Provided, however, that:

    (A) paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

     

     


     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    (b) The Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee bonus plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (h) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.


     

     

     

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Emeryville, State of California, on March 27, 2025.

     

    KYVERNA THERAPEUTICS, INC.

    By:

    /s/ Warner Biddle

    Name:

     Warner Biddle

    Title:

    Chief Executive Officer

    POWER OF ATTORNEY

    Know All Persons By These Presents, that each person whose signature appears below constitutes and appoints Warner Biddle and Ryan Jones, and each or any one of them, as his or her true and lawful attorneys-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

    SIGNATURE

    TITLE

    DATE

    /s/ Warner Biddle

    Chief Executive Officer and Director

    March 27, 2025

    Warner Biddle

    (Principal Executive Officer)

    /s/ Ryan Jones

    Chief Financial Officer

    March 27, 2025

    Ryan Jones

    (Principal Financial and Accounting Officer)

    /s/ Ian Clark

    Chairperson of the Board

    March 27, 2025

    Ian Clark

     

    /s/ Mert Aktar

    Director

    March 27, 2025

    Mert Aktar

    /s/ Fred E. Cohen, M.D., D. Phil.

    Director

    March 27, 2025

    Fred E. Cohen, M.D., D. Phil.

    /s/ Steve Liapis, Ph.D.

    Director

    March 27, 2025

    Steve Liapis, Ph.D.

     

     

    /s/ Christi Shaw

    Director

    March 27, 2025

    Christi Shaw

     

     

    /s/ Beth Seidenberg, M.D.

    Director

    March 27, 2025

    Beth Seidenberg, M.D.

     

     

    /s/ Daniel Spiegelman

    Director

    March 27, 2025

    Daniel Spiegelman

     

     

     

     

     

     


    Get the next $KYTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KYTX

    DatePrice TargetRatingAnalyst
    8/20/2025Outperform
    William Blair
    5/27/2025$5.00Neutral → Buy
    H.C. Wainwright
    10/10/2024$13.00Buy
    UBS
    10/9/2024$16.00Buy
    Rodman & Renshaw
    7/3/2024$8.00Neutral
    H.C. Wainwright
    3/4/2024$40.00Overweight
    Morgan Stanley
    3/4/2024$39.00Overweight
    JP Morgan
    3/4/2024$44.00Overweight
    Wells Fargo
    More analyst ratings

    $KYTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Pujols Mayobanex

    3 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)

    2/11/26 4:30:27 PM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Technology Officer Pujols Mayobanex

    4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)

    2/11/26 4:30:05 PM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Executive Chairperson Shaw Christi was granted 54,301 shares, increasing direct ownership by 326% to 70,935 units (SEC Form 4)

    4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)

    1/14/26 5:00:10 PM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KYTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer

    EMERYVILLE, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical stage biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced the appointment of Mayo Pujols as its Chief Technology Officer (CTO), effective February 9, 2026. Mr. Pujols brings more than 30 years of technical operations experience to the role with a deep background in leading late-stage and commercial manufacturing for cell and gene therapies. His work spans both large-scale and smaller biopharmaceutical companies with a proven track record of successfully advancing programs across their lifecycles. He succeeds Karen Walker, who is

    2/3/26 8:00:00 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference

    Advancing valuable commercial opportunity in stiff person syndrome (SPS) following landmark registrational data; Biologics License Application (BLA) submission anticipated in 1H 2026  First patient enrolled in registrational Phase 3 trial in generalized myasthenia gravis (gMG) Completed follow-on offering extends cash runway into 2028, expected to fully fund SPS BLA filing, commercial launch, and Phase 3 gMG trial Kyverna Board member, Christi Shaw, appointed as Executive Chairperson, further bolstering Company's CAR T commercialization experience; Ian Clark, former Chairperson, to remain on Board EMERYVILLE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. ((Kyver

    1/12/26 8:00:00 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference

    EMERYVILLE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. ((Kyverna, NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the J.P. Morgan 2026 Healthcare Conference in San Francisco on Wednesday, January 14th, 2026, at 9:45 a.m. PT. A live audio webcast of the presentation may be accessed via the Investors section of the Kyverna website at ir.kyvernatx.com. A replay of the webcast will be available on the website for 30 days following the conference. About Kyverna TherapeuticsKyverna Therapeutics, In

    1/5/26 8:00:00 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KYTX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Kyverna Therapeutics Inc.

    SCHEDULE 13G/A - Kyverna Therapeutics, Inc. (0001994702) (Subject)

    2/6/26 3:17:11 PM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kyverna Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)

    2/3/26 8:00:25 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kyverna Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

    8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)

    1/12/26 8:00:28 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KYTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair initiated coverage on Kyverna Therapeutics

    William Blair initiated coverage of Kyverna Therapeutics with a rating of Outperform

    8/20/25 8:57:26 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kyverna Therapeutics upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Kyverna Therapeutics from Neutral to Buy and set a new price target of $5.00

    5/27/25 9:06:20 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    UBS initiated coverage on Kyverna Therapeutics with a new price target

    UBS initiated coverage of Kyverna Therapeutics with a rating of Buy and set a new price target of $13.00

    10/10/24 7:37:04 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KYTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Seidenberg Beth C bought $999,998 worth of shares (133,333 units at $7.50) (SEC Form 4)

    4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)

    12/22/25 11:43:43 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Westlake Biopartners Opportunity Fund I, L.P. bought $999,998 worth of shares (133,333 units at $7.50) (SEC Form 4)

    4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)

    12/22/25 11:42:37 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KYTX
    Financials

    Live finance-specific insights

    View All

    Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome

    Landmark results could pave the way for miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease; Company on track to submit BLA for stiff person syndrome in 1H 2026  Miv-cel achieved statistically significant clinical benefit across all primary and secondary endpoints, reversing disability and eliminating immunotherapies after a single dose Miv-cel was generally well-tolerated with no high-grade CRS or ICANS observed SPS is a debilitating, progressive autoimmune disease with no FDA-approved therapies Company to host webcast today, December 15, 2025 at 8 am ET EMERYVILLE, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a c

    12/15/25 6:30:00 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome

    EMERYVILLE, Calif., Dec. 14, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced it will host a live webcast and conference call on Monday, December 15, 2025 at 8:00 am ET to review topline results from the registrational Phase 2 KYSA-8 clinical trial evaluating KYV-101 in stiff person syndrome (SPS). Conference Call Details Participants will need to register at the below-noted URL in order to listen and participate in the call. Once registered, participants will receive a dial-in phone number and unique PIN number which will be needed to join th

    12/14/25 2:30:00 PM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025

    Compelling results set new clinical standard in generalized myasthenia gravis (gMG), increasing confidence in the Company's registrational KYSA-6 Phase 3 MG trial 100% of patients achieved clinically meaningful responses in MG-ADL and QMG -- the co-primary endpoints of the Phase 3 trial -- with mean reductions of -8.0 pts and -7.7 points at 24 weeks KYV-101 was well-tolerated with no high-grade CRS and no ICANS observed, further supporting the consistent and manageable safety profile of KYV-101 Unprecedented results further reinforce KYV-101's potential to deliver durable, drug-free, disease-free remission with a single dose Company to host conference call today, October 29, 2025, at 8:0

    10/29/25 6:30:00 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KYTX
    Leadership Updates

    Live Leadership Updates

    View All

    Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer

    EMERYVILLE, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical stage biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced the appointment of Mayo Pujols as its Chief Technology Officer (CTO), effective February 9, 2026. Mr. Pujols brings more than 30 years of technical operations experience to the role with a deep background in leading late-stage and commercial manufacturing for cell and gene therapies. His work spans both large-scale and smaller biopharmaceutical companies with a proven track record of successfully advancing programs across their lifecycles. He succeeds Karen Walker, who is

    2/3/26 8:00:00 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

    Topline data for registrational Phase 2 trial of KYV-101 in stiff person syndrome (SPS) andBLA submission anticipated in 1H 2026 Registrational Phase 3 KYV-101 trial in myasthenia gravis (MG) to include ~60 patients with enrollment to initiate by year-end 2025; interim Phase 2 data expected in Q4 2025 Strong cash position to support upcoming milestones EMERYVILLE, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today reported its business highlights and financial results for the quarter ended June 30, 2025.   "The second quarter was

    8/12/25 4:02:00 PM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise

    Webcast to be held August 28, 2025, 11:00am ET EMERYVILLE, Calif., July 29, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. ((Kyverna, NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that the Company will host a webcast event with Key Opinion Leaders (KOLs) to discuss its neuroimmunology franchise. The event will take place on Thursday, August 28, 2025, from 11:00am to 1:30pm ET. Presentations will feature members of the Company's management team and the following renowned KOLs: Srikanth Muppidi, M.D., Stanford MedicineRicardo Grieshaber-Bouyer, M.D., Ph.D., FAU Erlangen-NümbergAiden Haghiki

    7/29/25 8:30:00 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KYTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Kyverna Therapeutics Inc.

    SC 13G - Kyverna Therapeutics, Inc. (0001994702) (Subject)

    11/12/24 7:23:31 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Kyverna Therapeutics Inc.

    SC 13G - Kyverna Therapeutics, Inc. (0001994702) (Subject)

    10/10/24 12:36:27 PM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D filed by Kyverna Therapeutics Inc.

    SC 13D - Kyverna Therapeutics, Inc. (0001994702) (Subject)

    5/3/24 5:57:02 PM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care